H.C. Wainwright assumed coverage of Mirum Pharmaceuticals (MIRM) with a Buy rating and $73 price target Mirum is a biopharmaceutical company developing and commercializing therapies for the treatment of rare diseases, the analyst tells investors in a research note. The firm says that considering the growth potential of the current commercial products and the “”strong” pipeline potential, Mirum at its current market valuation of $2.2B is attractive to a long-term investor.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $77 from $73 at Raymond James
- Buy Rating on Mirum Pharmaceuticals: Promising Phase 2b VANTAGE Study Results and Strong Market Potential
- Mirum’s volixibat shows ‘best-in-class potential,’ says Citi
- Mirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP
- Mirum Pharmaceuticals Reports Robust Q1 2025 Growth